# Harmony Biosciences Reports Record Q2 2026 Revenue and Shares Phase 1 Data for Pipeline Asset BP-205

> news · REPORTED · 2026-08-04

Harmony Biosciences reported record Q2 2026 WAKIX net revenue of $261.3 million, up 30% year over year, and reiterated full-year 2026 guidance of $1.0 to $1.04 billion. The company also shared favorable Phase 1 single ascending dose data for its orexin-2 agonist BP-205, demonstrating dose-proportional pharmacokinetics and no serious adverse events, and announced a CFO transition.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a pharmaceutical company developing and commercializing therapies for patients with rare neurological diseases, with its lead product WAKIX approved for excessive daytime sleepiness in narcolepsy.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-announces-record-q2-2026-revenue-shares-initial-clinical-data

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.